Houston-based Salarius Pharmaceuticals Inc. is a promising clinical-stage biotech company that is focused on developing new therapies for cancers with unmet medical needs. Its cutting-edge lead candidate, Seclidemstat (SP-2577), is a small molecular inhibitor currently in the Phase I/II clinical trial phase for the treatment of advanced solid tumors and Ewing sarcoma. Additionally, Salarius Pharmaceuticals offers SP-3164, another small molecular protein degrader that may hold significant promise in the treatment of hematological and solid tumors. Salarius Pharmaceuticals holds exclusive licensing rights with respect to patent rights protecting SP-2577 and related compounds through a strategic partnership with The University of Utah Research Foundation, as well as product development activities with the Cancer Prevention and Research Institute of Texas.
Salarius Pharmaceuticals's ticker is SLRX
The company's shares trade on the NASDAQ stock exchange
They are based in Houston, Texas
There are 1-10 employees working at Salarius Pharmaceuticals
It is salariuspharma.com
Salarius Pharmaceuticals is in the Healthcare sector
Salarius Pharmaceuticals is in the Biotechnology industry
The following five companies are Salarius Pharmaceuticals's industry peers: